共 50 条
- [21] Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaCLINICAL CANCER RESEARCH, 2015, 21 (14) : 3160 - 3169Brown, Jennifer R.Davids, Matthew S.Rodon, JordiAbrisqueta, PauKasar, Siddha N.Lager, JoanneJiang, JasonEgile, CoumaranAwan, Farrukh T.
- [22] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitorsONCOTARGET, 2017, 8 (29) : 47725 - 47740Rewcastle, Gordon W.Kolekar, SharadaBuchanan, Christina M.Gamage, Swarna A.Giddens, Anna C.Tsang, Kit Y.Kendall, Jackie D.Singh, RipudamanLee, Woo-JeongSmith, Greg C.Han, WeipingMatthews, David J.Denny, William A.Shepherd, Peter R.Jamieson, Stephen M. F.
- [23] Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer modelsCANCER RESEARCH, 2011, 71Bao, RudiWang, DagongQu, HuiYin, LingXu, Guang-XinDellaRocca, StevenBorek, MylissaAtoyan, RuzannaForrester, JeffreySamson, MariaWang, JingZhai, Hai-XaioChan, MendyLai, Cheng-JungCai, XiongQian, Changgeng
- [24] Sequential Application of a Cytotoxic Nanoparticle and a PI3K Inhibitor Enhances Antitumor EfficacyCANCER RESEARCH, 2014, 74 (03) : 675 - 685Pandey, AmbarishKulkarni, AshishRoy, BhaskarGoldman, AaronSarangi, SasmitSengupta, PoulomiPhipps, ColinKopparam, JawaharOh, MichaelBasu, SudiptaKohandel, MohammadSengupta, Shiladitya
- [25] Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor ActivityACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (11): : 809 - 813Liu, Kevin K-C.Zhu, JinJiangSmith, Graham L.Yin, Min-JeanBailey, SimonChen, Jeffrey H.Hu, QiyueHuang, QinhuaLi, ChunzeLi, Qing J.Marx, Matthew A.Paderes, GenevieveRichardson, Paul F.Sach, Neal W.Walls, MarlenaWells, Peter A.Zou, Aihua
- [26] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 20, pg 233, 2014)CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2192 - 2192Rodon, JordiShapiro, G., IBedell, C.Kwak, E. L.Baselga, J.Brana, I
- [27] Discovery of a novel and potent mutant-selective inhibitor of PI3KαCANCER RESEARCH, 2024, 84 (06)Gao, MingmingQi, ChaoLi, ZhentianFan, QipengWang, LiyangZhou, FeiYou, LinZheng, HewenLi, YuWu, LiangxingYao, WenqingLiu, Phillip C.
- [28] Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitorBIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (14) : 3917 - 3924Hamajima, ToshihiroTakahashi, FumieKato, KojiSugano, YukihitoYamaki, SusumuMoritomo, AyakoKubo, SatoshiNakamura, KojiYamagami, KaoruHamakawa, NozomuYokoo, KojiFukahori, Hidehiko
- [29] Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisibSCIENTIFIC REPORTS, 2023, 13 (01)Till, Kathleen J.Abdullah, MariahAlnassfan, TaheraJanet, Gallardo ZapataMarks, ThomasComa, SilviaWeaver, David T.Pachter, Jonathan A.Pettitt, Andrew R.Slupsky, Joseph R.
- [30] Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisibScientific Reports, 13Kathleen J. TillMariah AbdullahTahera AlnassfanGallardo Zapata JanetThomas MarksSilvia ComaDavid T. WeaverJonathan A. PachterAndrew R. PettittJoseph R. Slupsky